Shock wave or splint? new study tests best treatment for trigger finger
NCT ID NCT06296017
First seen Jun 26, 2026 · Last updated Aug 06, 2026 · Updated 2 times
Summary
This study compares two common treatments for trigger finger: shock wave therapy and a finger splint. Researchers will enroll 54 adults with early-stage trigger finger to see which approach better reduces pain and improves hand function. The goal is to find out if shock wave therapy offers any advantage over the simpler splint.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Extracorporeal Shock Wave Therapy (ESWT) and trigger finger splint
- What this could lead to
- If this works, it could show that shock wave therapy is a good non-surgical option for easing pain and improving hand function in early trigger finger.
- What could go wrong
- This is a small, early-stage study with only 54 people. The results may not apply to everyone, and shock wave therapy might not be better than a simple splint.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 54 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2025
- Expected to finish
-
Aug 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Volunteering * Being between the ages of 18-65 * Being diagnosed with stage 1 or stage 2 (according to the Froimson classification) trigger finger * Having the language and cognitive skills to answer the questionnaires used in the evaluation Exclusion Criteria: * Being pregnant * Having an inflammatory disorder * Having had surgery on the hand/wrist * Having a neurological disease * NSAIDs, painkillers, etc. being on medication * De Quervain's tenosynovitis, carpal tunnel syndrome
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Stenosing tenosynovitis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Feray Karademir
RECRUITINGAnkara, 06100, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Does mixing numbing agent into steroid shots ease hand pain?
- Splint showdown: which brace best beats trigger finger?
- Can light therapy unlock stiff fingers?
- Sugar solution may rival steroids for stuck fingers
- Numbing patch eases injection pain for trigger finger sufferers
- Hand rehab revolution? early data may predict recovery months ahead